Treatment of non-small cell lung cancer: Focus on pemetrexed disodium

Josephine Feliciano, Jyoti Patel

Research output: Contribution to journalReview articlepeer-review


Pemetrexed (Alimta, Eli Lilly) is a multi-targeted anti-folate originally approved for its use in malignant mesothelioma. Based on results from phase III clinical investigations, it is now approved for use as a single agent in the second-line setting and in combination with platinum therapy in the first-line setting for advanced non-small cell lung cancer. It is also under investigation in earlier stages of non small cell lung cancer including in the adjuvant setting and with radiation. It has shown to be particularly efficacious for non-squamous histology and is well tolerated. Toxicity includes, but is not limited to hematologic toxicity and gastrointestinal toxicity, which are minimized by vitamin B12 and folic acid supplementation. Recent analyses also suggest cost-effectiveness of this agent in patient with advanced, non-squamous cell non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)737-748
Number of pages12
JournalClinical Medicine Insights: Therapeutics
StatePublished - Jan 1 2010
Externally publishedYes


  • Advanced
  • Lung cancer
  • Pemetrexed

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science


Dive into the research topics of 'Treatment of non-small cell lung cancer: Focus on pemetrexed disodium'. Together they form a unique fingerprint.

Cite this